Hepatocyte Growth Factor Overexpression in the Islet of Transgenic Mice Increases Beta Cell Proliferation, Enhances Islet Mass, and Induces Mild Hypoglycemia

Abstract

Hepatocyte growth factor (HGF) is produced in pancreatic mesenchyme-derived cells and in islet cells. <i>In vitro</i>, HGF increases the insulin content and proliferation of islets. To study the role of HGF in the islet <i>in vivo</i>, we have developed three lines of transgenic mice overexpressing mHGF using the rat insulin II promoter (RIP). Each RIP-HGF transgenic line displays clear expression of HGF mRNA and protein in the islet. RIP-mHGF mice are relatively hypoglycemic in post-prandial and fasting states compared with their normal littermates. They display inappropriate insulin production, striking overexpression of insulin mRNA in the islet, and a 2-fold increase in the insulin content in islet extracts. Importantly, beta cell replication rates <i>in vivo</i> are two to three times higher in RIP-HGF mice. This increase in proliferation results in a 2–3-fold increase in islet mass. Moreover, the islet number per pancreatic area was also increased by approximately 50%. Finally, RIP-mHGF mice show a dramatically attenuated response to the diabetogenic effects of streptozotocin. We conclude that the overexpression of HGF in the islet increases beta cell proliferation, islet number, beta cell mass, and total insulin production <i>in vivo</i>. These combined effects result in mild hypoglycemia and resistance to the diabetogenic effects of streptozotocin.